Combination drug therapy before surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a combination of three drugs (culmerciclib, letrozole, and two HER2-targeting drugs) given before surgery to shrink breast cancers that are hormone-receptor positive and HER2 positive.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer must be both HR-positive (ER ≥10%, PR ≥10%) and HER2-positive.
- Your cancer must be stage II or III (not stage IV/metastatic).
- You must not have received prior systemic treatment (chemotherapy, hormone therapy, or HER2-targeted therapy) for this breast cancer.
- You must have an ECOG performance status of 0 or 1 (fully active or restricted but ambulatory).
- You must have adequate organ function and no severe heart problems (LVEF below normal is excluded).
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combination treatment plans given before breast surgery (neoadjuvant therapy) for ER-positive and HER2-positive stage II–III breast cancer. It aims to see which plan works better to shrink the tumor and improve outcomes.
This trial tests whether a combination of targeted therapies and hormone therapy can shrink triple-positive breast cancer before surgery. It is for women with stage II or III breast cancer that has not yet been treated.
This trial tests a combination of three targeted drugs (trastuzumab, pertuzumab, and tucatinib) without chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink tumors effectively while avoiding chemotherapy side effects.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a new drug called TQB2102 combined with standard chemotherapy (TCbHP) as a first treatment before surgery for HER2-positive early breast cancer. The goal is to see if this combination works better than the current standard therapy.
This trial tests a new combination of two targeted drugs (Trastuzumab Rezetecan and Pertuzumab) given before surgery for HER2-positive breast cancer. The goal is to see if this approach shrinks tumors more effectively.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.